Apotex, Ranbaxy End Pay-For-Delay Suit Over Narcolepsy Med
By Rachel Graf ( July 7, 2017, 5:49 PM EDT) -- A Pennsylvania federal judge on Friday ended Canadian pharmaceutical company Apotex's pay-for-delay suit accusing generic-drug maker Ranbaxy of violating antitrust laws by accepting a settlement with Cephalon that improperly delayed generic alternatives to the narcolepsy medication Provigil from entry into the market....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.